Industry news

Science and Technology cooperation to grow between India and Russia

Russia & India Report

There is a gamut of bilateral links and inter-governmental mechanisms in diverse science and technology sectors beyond defence and nuclear power.

Biologics Research Promises to Bolster the Future of Medicine

The Pharmaceutical Research and Manufacturers of America (PhRMA)

America’s biopharmaceutical research companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases. Many biologics are made from a variety of natural sources—human, animal or microorganisms. Like small-molecule drugs, some biologics are intended to treat diseases and medical conditions. Other biologics are used to prevent or diagnose disease.

America’s biopharmaceutical research companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases

The Pharmaceutical Research and Manufacturers of America (PhRMA)

America’s biopharmaceutical research companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report from PhRMA. The medicines and vaccines – all in human clinical trials or under review the U.S. Food and Drug Administration (FDA) – include 338 monoclonal antibodies, 250 vaccines, 93 recombinant proteins, 60 cell therapies, 46 gene therapies and 30 antisense medicines.  

RUSNANO invests $825 000 in Bioptix Company

venture-news.ru

RUSNANO, JSC will invest $825 000 in Bioptix Diagnostics, Inc within the next funding round. According to the press service of the nanotech company, this decision was made by RUSNANO's board of directors. Bioptix Diagnostics, Inc. plans to invest the funds raised in further development of label-free bio-detectors of second generation, and start their sales. 

The reed that bends: pharma needs to adapt to cultural sensitivities

PMLiVE

Pharmaceutical companies are increasingly looking beyond core international markets to drive future revenues. As traditional markets mature, multinationals have identified the developing nations as their most likely growth engine. Optimising the so-called 'emerging markets' has itself emerged as a key strategy across the industry. 

M&A deals in the pharmaceutical industry: Russia and worldwide

Alexey Volostnov, pharmaphorum.com

Traditionally M&A deals present a large opportunity for pharmaceutical and biotechnology companies to expand their business operations significantly and enter new markets. It’s also one way to increase the declining revenues due to the expiration of a large number of product patents.

Moscow included in the top ten cities favorable for business

Venture Business News

According to a study conducted by Institute for Emerging Market Studies of the Skolkovo business school - Ernst & Young (IEMS), Moscow is one of the most business-friendly cities. 

BRICK countries racing ahead in innovation and research

Victor Kuzmin, Russia & India Report

Brazil, Russia, India, China and South Korea (BRICK) are joining efforts to develop innovative solutions, an approach that might give them a technological edge over the G7 states in the coming years.

Russian government to develop domestic production of vaccines

The Pharma Letter

The Russian government is considering investing in the domestic production of vaccines, by building a new and modernization of the already existing factories, as well as creating conditions for the improvement of quality of their production. This is expected to be part of the state strategy of drug supply in Russia until 2025, which was recently approved by the Russian government. 

Russian Government's Initiatives to Develop the Medical Devices Market

Irina Naumenko, The Moscow Times

Medical devices in Russia are feeling the heat from the state's interest in the industry. This interest has not only resulted in a series of new regulations passed over the last few months, but also several very exciting drafts now under discussion.